ClinicalTrials.gg
WithdrawnNCT06938711Updated Apr 22, 2025

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

A Phase 1/2 interventional study of Elacestrant and Onapristone in Breast Cancer, sponsored by Context Therapeutics Inc.. Withdrawn at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-22.

Sponsored by Context Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

How we know · 6 judgments

Why this study was withdrawn
Change in corporate strategy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This is a rollover study for patients enrolled in the discontinued ELONA clinical trial (ONA-XR-103) with the primary objective to characterize the safety of elacestrant in combination with onapristone either alone or in combination.

02

Conditions studied

  • Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Lead sponsor

Context Therapeutics Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is currently enrolled in the ELONA clinical study (ONA-XR-103) and receiving onapristone or elacestrant, either alone or in combination.
  • Patient is currently benefiting from the treatment in the ELONA clinical study, as determined by the investigator.
  • Patient currently has no evidence of progressive disease, as determined by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing (lactating) women.
  • Female patients of (e.g., are menstruating) who do not agree to abstinence or, if sexually active, do not agree to the use of highly effective , throughout the study and for up to 30 days after stopping study treatment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Elacestrant / Onapristone

    Elacestrant and Onapristone combination

    Drug: Elacestrant · Drug: Onapristone

Interventions

  • Elacestrant 200mg once daily oral dosing in cycles of 28 days.

    Also known as: RAD1901

  • Onapristone 40mg twice daily oral dosing in cycles of 28 days.

06

What researchers measure

Primary outcomes

  1. Characterize the safety of elacestrant in combination with onapristone.

    Monitor the treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: 7 months

07

Study locations

1 site
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2023; primary completion for Nov 2023, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2023
First posted
Apr 22, 2025
StartEst.
Jun 2023
Primary completionEst.
Nov 2023
CompletionEst.
Dec 2023
Last update
Apr 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06938711
Lead sponsor
Context Therapeutics Inc.
Responsible party
Sponsor
First posted
Apr 22, 2025
Start date
Jun 2023 (estimated)
Primary completion
Nov 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Apr 22, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Onapristone

Start the discussion